Short Description: Solid tumor treatment is limited by frequent disease recurrence, forcing patients to endure multiple therapies with suboptimal outcomes and severe side effects. COPE-GENE is a percutaneous platform combining electroablation and electroporation-based gene therapy for the treatment of solid tumors. It enables efficient tumor destruction, payload delivery, and immune activation in a single minimally invasive procedure, improving efficacy and reducing costs for interventional oncology.
Lessons Learned: We initially believed the primary challenges were low treatment durability and side effects. Through customer discovery, we learned that streamlining treatment protocol, achieving homogeneous therapeutic distribution, and leveraging the expanding treatment armamentarium are also of critical concern to interventional radiologists and other healthcare providers treating liver cancer.
Names and Affiliation of Team members:
Terence Gade, Faculty, University of Pennsylvania, Perelman School of Medicine, Radiology
Giang Hoang, MD-PhD Candidate, University of Pennsylvania, School of Engineering and Applied Science, Bioengineering
Stephen Kadlecek, Faculty, University of Pennsylvania, Perelman School of Medicine, Radiology